Article
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
Rating:
0.0
Views:
99
Likes:
1
Library:
1
Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly .
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value